LMAT
LeMaitre Vascular, Inc.
Healthcare · Medical - Instruments & Supplies
Undervalued·Quality 100·RSI 57·DCF -19%·Conviction 65
Investment Thesis — LeMaitre Vascular, Inc.
The market misprices LeMaitre Vascular as a slow-growth, niche medtech supplier, overlooking its accelerating operating leverage and underappreciated pricing power in a consolidating vascular device market. As competitors retrench and hospitals seek reliable, specialized partners, LMAT's unique portfolio and distribution moat will drive outsized margin expansion versus consensus. Investors are paying a premium multiple for perceived safety, but not for the company's latent earnings inflection.
Catalysts
- Announcement of major hospital supply agreements or distribution partnerships
- Evidence of sustained margin expansion in quarterly results
- Competitor exits or product recalls leading to market share gains
Risk Factors
- Hospital budget cuts or delayed procedures impacting demand
- Regulatory or reimbursement changes reducing pricing power
- Operational missteps in scaling distribution or integrating new products
Key Debates
Fwd P/E of 35x justifies 23% revenue growth into FY25
LMAT reaches $101.50 price target by Q3 2024
Recent momentum pushes LMAT's RSI above 70 by Q4